Preiningerova Jana Lizrova, Vachova Marta
Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital in Prague, Praha 2, Praha, 121 08, Czech Republic.
Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, Faculty of Medicine and General University Hospital in Prague, Praha, Czech Republic.
Ther Adv Neurol Disord. 2017 Jan;10(1):67-75. doi: 10.1177/1756285616671887. Epub 2016 Oct 19.
Daclizumab is a humanized monoclonal antibody that binds to the α subunit (CD25) of the interleukin-2 receptor and favorably modulates the immune environment in multiple sclerosis (MS). Blockage of CD25, among other effects, causes expansion and enhanced function of regulatory CD56 natural killer cells, which seems to be the leading mechanism of action in MS. Phase II and III clinical trials have demonstrated that monthly subcutaneous injections of daclizumab high yield process (DAC HYP) 150 mg in patients with relapsing MS led to a significant reduction of annualized relapse rate and decreased number of contrast-enhanced lesions on brain magnetic resonance imaging. Treatment with DAC HYP had efficacy superior to treatment with weekly injections of interferon β1a. This review summarizes the development of and clinical experience with daclizumab in MS.
达克珠单抗是一种人源化单克隆抗体，可与白细胞介素-2受体的α亚基（CD25）结合，从而对多发性硬化症（MS）的免疫环境产生有利调节作用。阻断CD25等作用可导致调节性CD56自然杀伤细胞的扩增和功能增强，这似乎是MS的主要作用机制。II期和III期临床试验表明，复发型MS患者每月皮下注射150 mg的达克珠单抗高产率工艺（DAC HYP）可显著降低年化复发率，并减少脑磁共振成像上对比增强病灶的数量。DAC HYP治疗的疗效优于每周注射干扰素β1a的治疗。本综述总结了达克珠单抗在MS中的研发情况和临床经验。
